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Abstract 
Nowadays, the most efficient form of intravesical immunotherapy for superficial transitional 
cell carcinoma of the urinary bladder is the instillation of bacillus Calmette-Guérin (BCG), 
proceeding from an attenuated strain of Mycobacterium bovis. In up to 40% of cases, its 
instillation is associated with significantly elevated prostate-specific antigen (PSA) levels. In 
these cases, prostate biopsy should be withheld for 3 months and PSA should be monitored. 
Bacillary prostatitis is a rare occurrence in patients treated with intravesical BCG 
immunotherapy. Although symptomatic bacillary prostatitis is even rarer, it is the worst type 
of this condition. The aims of this study are to report a case of bacillary prostatitis as a rare 
adverse effect of intravesical BCG immunotherapy and to make a theoretical review about 
how to manage this complication. A 58-year-old man, former smoker, underwent a 
transurethral resection of the bladder in February 2004 because of a papillary transitional 
cell carcinoma of the bladder (pT1G2N0M0). After surgery, BCG instillation therapy was 
given in a total of 15 instillations, the last one in March 2007. In the last 3 months of therapy, 
until May 2007, a progressive increase in his PSA level was registered, and he underwent a 
prostate biopsy revealing granulomatous prostatitis of bacillary etiology. The semen culture 
was positive for M. bovis. After 3 months of a two-drug (isoniazid and rifampin) 
antituberculous regimen, the semen culture became negative and the PSA level decreased. 
The early identification of intravesical BCG immunotherapy complications allows their 
effective treatment. However, when a histological diagnosis of asymptomatic granulomatous 
prostatitis is made, the execution and type of treatment are controversial. Case Rep Oncol 2012;5:80–83 
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Introduction 
Superficial transitional cell cancer comprises carcinomas in situ (CIS), papillary 
tumours limited to the mucosa, papillary tumours involving the lamina propria but not 
the muscle layer of the bladder, or any combination of these. The primary treatment for 
CIS is transurethral resection (TUR), although it is often not curative. 
Intravesical therapy is an integral part of treatment in patients with superficial 
urothelial carcinoma of the bladder. Bacillus Calmette-Guérin (BCG) has been in use as 
an intravesical immunotherapeutic agent since the 1980’s and is the most effective 
proven form of this kind of therapy. BCG Immunotherapeutic is a freeze-fried 
preparation made from a culture of the Connaught strain of BCG, which is an attenuated 
strain of the living bovine tubercle bacillus Mycobacterium bovis. BCG 
Immunotherapeutic promotes local inflammatory effects that are associated with the 
elimination or reduction of superficial cancerous lesions of the urinary bladder. 
Although the exact mechanism by which this is accomplished is unknown, the 
antitumour effect appears to be T lymphocyte dependent. Intravesical immunotherapy 
is generally safe. There is a high incidence of local, usually self-limited, relatively minor 
side effects, and infrequent, potentially severe local and systemic side effects [1]. 
Bacillary prostatitis is a local complication of BCG immunotherapy. It can be 
suspected when there are symptoms like or a suggestive history of irritative voiding, 
male factor infertility, sterile urethral discharge, terminal hematuria, perineal pain, 
swelling and drainage, or when an isolated increase in the prostate-specific antigen 
(PSA) level is detected, corresponding to the histological diagnosis. Symptomatic 
bacillary prostatitis must be treated with antituberculous agents for 3 months. In cases 
with asymptomatic elevated PSA levels, the prostate biopsy should be withheld and 
PSA monitored. Histology is indicated when there is persistent increased PSA for more 
than 3 months and, if positive for granulomatous prostatitis, the optimal management 
is not established [2]. Primary treatment includes definitive discontinuation of 
intravesical immunotherapy. All patients must be advised to use condoms during 
intercourse because sexual transmission via infected semen has been reported to result 
in a vaginal tuberculous ulcer [2]. 
Antituberculous treatment is an option that should be discussed in a 
multidisciplinary way as well as with the patient. BCG is a mycobacterium sensitive to 
all currently used antituberculous drugs, with the exception of pyrazinamide. The 
pharmacokinetics of the antituberculous drugs frequently prevents them of achieving 
the optimal intracellular bactericidal concentrations. There are indicated combinations 
such as the two-drug combination with isoniazid 300 mg/day and rifampicin 600 
mg/day, the three-drug combination of the two above-mentioned drugs plus 
ethambutol 1,200 mg/day, or the combination rifampicin plus ofloxacin 200 mg b.i.d. 
This last combination uses the group of antibiotics (quinolones) also indicated in cases 
of unsuccessful antituberculous therapy. Further outpatient care includes periodical 
examination of the semen cultures to monitor treatment. If the results are positive after 
3 months of therapy, bacterial resistance to the current drug regimen or patient 
noncompliance – which is not unusual – should be strongly suspected. Most patients 
can be cured when treated early with a multiple-drug regimen [2]. Case Rep Oncol 2012;5:80–83 
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Case Report 
In February 2004, a 58-year-old man, former smoker, presented to his doctor complaining of 
haematuria starting 2 months earlier. Since ultrasonographic examination revealed an intravesical 
neoformation, the patient underwent a TUR of the bladder. The histology confirmed the neoplastic 
nature of the surgical specimen, whose histology was described as follows: ‘superficial papillary 
transitional cell carcinoma pT1G2N0M0 without vascular, lymphatic and perineural invasion’. 
Two weeks after surgery, according to the decision made by a multidisciplinary group from the 
Department of Oncology, the patient was started on BCG instillation therapy consisting of an 
induction course followed by maintenance therapy with a total of 15 instillations, the last one in 
March 2007. BCG was administered intravesically weekly for 6 weeks and in weeks 13, 14 and 15, 
with an additional single instillation in months 6, 12, 18, 24, 30 and 36. This therapeutical scheme was 
not interrupted or postponed, since the patient tolerated it very well, showing no immediate 
complications. During the 2 years of intravesical therapy, he was asymptomatic. 
In the last 3 months of therapy, until May 2007, a progressive PSA increase was registered, with 
the PSA level being at last 6.0 μg/l. In May 2007, the patient underwent a prostate biopsy revealing 
‘granulomatous prostatitis of bacillary etiology’. After a multidisciplinary meeting with members from 
the Departments of Oncology and Urology, it was decided to administer antibacillary treatment. The 
patient received a two-drug regimen of antituberculous therapy with isoniazid 300 mg/day and 
rifampin 600 mg/day, with associated pyridoxine/vitamin B6 75 mg/day to prevent neuropathy 
associated with isoniazid use. 
The semen culture was analyzed and stained positive for acid-fast bacilli, confirming M. bovis 
infection a posteriori as well as excluding other affected organs and systems with thoracic X-ray and a 
nephro-computerized tomography, both unaltered. The plan was (1) to additionally prescribe 
ethambutol if renal affection was verified (which was not the case); (2) to test the infection 
eradication by doing another semen culture after 3 months of therapy, and (3) if the culture was 
negative, to stop the antituberculous agents. The patient tolerated the therapeutic regimen very well, 
with no side effects reported. The semen culture at the third month was negative for any kind of 
infection, so the antituberculous treatment was stopped in September 2007. Nowadays, the patient is 
doing well and remains asymptomatic, with a PSA level of 1.2 μg/l in November 2007 that remained 
1.1 μg/l at the last urology visit in December 2011. 
The Portuguese Sanitary Authority (INFARMED) and the pharmaceutical company (Aventis 
Pasteur) were notified about the occurrence of this rare adverse event. 
Discussion and Conclusion 
Intravesical therapy has been established as both an alternative to radical surgical 
treatment for CIS and as a prophylaxis for its recurrence. In superficial papillary 
tumours, intravesical therapy has significantly increased the time to recurrence when 
administered for prophylactic purposes following TUR [1]. 
The early identification of intravesical BCG immunotherapy complications allows 
their effective treatment with complete symptom regression. The most common local 
reactions are transient dysuria and urinary frequency, which occur in 26 and 14%, 
respectively, during the induction course and in 46 and 34%, respectively, during 
maintenance therapy. Serious genitourinary adverse events like bacterial urinary tract 
infection, epididymo-orchitis, urethral obstruction and renal abscess have been 
reported to be present in <0.5% of cases. The most serious adverse effect is systemic 
BCG reaction, defined as the presence of fever, pneumonitis or hepatitis, which is even 
rarer [3]. Case Rep Oncol 2012;5:80–83 
DOI: 10.1159/000336445 
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Intravesical BCG therapy is associated with significantly elevated PSA levels in up to 
40% of cases. In the majority of them, granulomatous prostatitis is asymptomatic and 
not diagnosed. It is transient and self-limited, and treatment is not required [4]. 
Pathologic evidence of granulomatous prostatitis with acid-fast bacilli is a common 
complication after this kind of therapy, and its incidence is far higher than the reported 
incidence of symptomatic granulomatous prostatitis. The duration of therapy is a 
determinant factor in the induction of the granuloma type [5]. The importance of 
asymptomatic granulomatous prostatitis, histologically diagnosed after a more than 3-
month history of an increased PSA level, is unknown. It is known that identifying BCG 
complications early, preventing them when possible and managing them efficiently is 
critical, as most complications are preventable [6]. 
In the presented case report, the progressive PSA increase was a major concern for 
both the patient and the physician, leading to the prostatic biopsy. After the diagnosis 
of granulomatous prostatitis of bacillary etiology was made, treatment with 
antituberculous agents was started, resulting in a consequent decrease in PSA and 
negative semen cultures. 
In cases where a histological diagnosis of asymptomatic granulomatous prostatitis 
has been established, the execution and type of treatment are controversial. There is no 
certainty about its self-limited character, and we cannot be sure about the safety and 
side effects of the antibacillary therapy [6]. On the other hand, we must take into 
account the psychological impact of having a disease that has an effective treatment 
(with antituberculous agents) and accepting the decision not to treat it. It is much more 
comforting for the patient and his physician to follow a therapy. Thus, these cases must 
be discussed in a multidisciplinary way as well as together with the patient in order to 
achieve a balanced decision. 
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